InstalabLoading...
InstalabLoading...
Estrone is one of the three main human estrogens, alongside estradiol and estriol. In premenopausal women, estradiol is the dominant and most biologically potent estrogen. After menopause, ovarian estradiol production declines sharply and estrone becomes the predominant circulating estrogen. In adult men, estrone is also a major circulating estrogen.
Estrone is produced primarily through a process called aromatization. Aromatase is an enzyme that converts androgens, which are typically thought of as male sex hormones, into estrogens. Specifically, aromatase converts androstenedione into estrone. This conversion occurs largely in adipose tissue, meaning body fat, but also in muscle, skin, brain, and other tissues.
The gene that encodes aromatase is called CYP19A1, and genetic differences in this gene can influence circulating estrone levels. Because adipose tissue is a major site of aromatase activity, body composition plays a central role in determining estrone concentrations.
Estrone is not just an endpoint hormone. It acts as a reservoir for estradiol. Through enzymes known as 17 beta hydroxysteroid dehydrogenases, estrone can be converted into estradiol within tissues. This local conversion allows tissues to regulate their own estrogen exposure independently of blood levels.
In postmenopausal women, a meaningful portion of circulating estradiol originates from peripheral conversion of estrone. In practical terms, estrone helps maintain baseline estrogen signaling after ovarian production declines.
Estrogen signaling occurs through estrogen receptors, which are proteins inside cells that bind estrogen and alter gene expression. Estrone binds these receptors with lower affinity than estradiol, meaning it produces a weaker signal. Even so, estrone contributes to bone remodeling, lipid metabolism, vascular function, brain signaling, and immune regulation.
Bone remodeling refers to the constant cycle of bone breakdown and rebuilding. Estrogen reduces bone resorption, which is the breakdown side of this cycle. Severe estrogen deficiency, such as in aromatase deficiency, leads to unfused growth plates, tall stature, and osteoporosis in both men and women. This highlights the essential role of estrogens, including estrone as a precursor, in skeletal integrity.
Estrone levels often reflect metabolic state. Because aromatase activity increases with adipose tissue mass, higher body fat is strongly associated with higher estrone. Obese postmenopausal women tend to have substantially higher estrone levels than lean women. In men, higher body mass index is also associated with higher estrone and estradiol.
From a healthspan perspective, estrone can function as a proxy for peripheral estrogen production driven by adiposity. Persistently elevated levels may track with higher cardiometabolic and hormone related cancer risk.
Estrone and estradiol do not always exert identical biological effects. Experimental data suggest that estrone may promote inflammatory signaling in certain contexts, including activation of NFκB, a transcription factor that turns on genes involved in inflammation. Chronic low grade inflammation contributes to metabolic dysfunction and cancer development.
In breast tissue, higher ratios of estrone relative to estradiol within tumors have been associated with increased tumor initiating stem cell activity in estrogen receptor positive breast cancer. This suggests that the balance between different estrogens, not just total estrogen, may influence tumor behavior.
Elevated estrone is most commonly driven by increased aromatization. Obesity is the primary contributor because of greater substrate availability and higher aromatase activity in adipose tissue. Polycystic ovary syndrome, characterized by elevated androgens such as androstenedione, can also increase estrone through excess substrate conversion.
With aging, estrone levels may remain stable or even rise modestly in some women despite declining adrenal precursors. Changes in body composition and peripheral conversion likely explain this pattern.
The liver metabolizes estrogens into conjugated forms such as estrone sulfate, which serves as a circulating storage form. Liver disease can alter estrogen metabolism and clearance, potentially changing circulating levels. Interpretation requires clinical context because patterns vary by condition.
Lower estrone levels are typically seen in individuals with low body fat, caloric restriction, or significant weight loss. Reduced adipose mass lowers aromatase activity and substrate availability. Aromatase deficiency, whether genetic or medication induced through aromatase inhibitors used in breast cancer treatment, leads to very low estrone and estradiol levels and is associated with rapid bone loss.
In frail older adults, very low estrone may reflect reduced adrenal androgen production and diminished peripheral conversion.
Estrone is less about a single optimal number and more about what it signals. High estrone often indicates increased adiposity and aromatase activity. Very low estrone may signal insufficient estrogen activity, with implications for bone density and possibly vascular health.
Interpreting estrone alongside estradiol, sex hormone binding globulin, body composition, and overall clinical context provides a more complete picture of endocrine and metabolic health.